Semaglutide® providers &
prescriptions in Concord, NC
Verified Semaglutide providers in Concord, NC. Checked against the NPI registry, never ranked by who pays us.[7]
Find a Semaglutide provider in North Carolina.
Every entry is checked against the federal NPI registry. We do not accept payment for placement.
How to get Semaglutide in Concord.
30 GLP-1 prescribers and 7 local resource types are on record for Concord, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm North Carolina’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.
Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]
In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]
Community health · CDC
Weight & metabolic health in Concord
Concord, North Carolina has a population of 105,240 people. The adult obesity rate in Concord is an age-adjusted estimate of 33.1%, 1.4 percentage points below the North Carolina state rate of 34.5%. Diagnosed diabetes reaches 10.1% of adults in Concord. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 21.9% of adults in Concord.
- of Concord adults have obesity
- 33.1%
- diagnosed diabetes
- 10.1%
- no regular physical activity
- 21.9%
Age-adjusted estimates for Concord, community figures, not individual risk. CDC PLACES, 2025 release.
The prescription is one part. Here is the rest, in Concord.
Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Concord, NC, ordered as the registry lists them, never by who pays us.
Gyms near you
A gym gives you the regular movement that keeps muscle while the weight comes off.
Fitness clubs and recreation centers
Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.
What the trials actually showed.
We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Semaglutide (semaglutide) prescribers and clinics, never ranked by who pays us.
Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]